AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Hepion Pharmaceuticals In... (HEPA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.17

-0.02 (-9.57%)

At close: Feb 21, 2025, 3:45 PM

undefined% (undefined)

Bid	0.17
Market Cap	1.79M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.4
PE Ratio (ttm)	-0.04
Forward PE	n/a
Analyst	Hold

Ask	0.17
Volume	4,720,122
Avg. Volume (20D)	20,467,886
Open	0.17
Previous Close	0.19
Day's Range	0.17 - 0.18
52-Week Range	0.12 - 3.33
Beta	undefined

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 10, 2014

Employees 22

Stock Exchange NASDAQ

Ticker Symbol HEPA

Website https://www.hepionpharma.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for HEPA stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

-58.05%

Hepion Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

2 months ago

-7.15%

Hepion Pharmaceuticals shares are trading lower. The company announced the termination of a merger agreement with Pharma Two B.

News

7 months ago · benzinga.com

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination prod...

10 months ago · investorplace.com

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. A press release from the company notes that it is wi...

1 year ago · zacks.com

Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet

The consensus price target hints at a 674.1% upside potential for Hepion Pharmaceuticals, Inc. (HEPA). While empirical research shows that this sought-after metric is hardly effective, an upward trend...